KRAS mutation is found in several cancers such as colorectal, lung, thyroid, pancreatic, cholangiocarcinoma. The KRAS mutations are often found on codons 12 and 13 of the exon 2, and lead to abnormal change of growth signal of the p21-ras protein. This abnormal change involved with cell growth and division may cause the process of cancer development by delivering the signal in excess. Existence of KRAS mutations is often related with a prognostic marker to drug response. For example, KRAS mutation is considered a strong prognostic marker for drug response of tyrosine kinase inhibitors such as gefitinib (Iressa) or erlotinib (Tarceva). Recently, KRAS mutation is often detected in colorectal cancer and may be related with drug response to cetuximab (Erbitux) or panitumumab (Vectibix) that is used for colon cancer therapy. Therefore, examination of KRAS mutation is needed to determine drug resistance of patients with colorectal or lung cancers and will be helpful for cancer therapies.
CAT NO.
PNAC-1006
Total 40 KRAS mutations can be detected.
|
Mutations
|
Size
|
|
Codon 12
|
Codon 13
|
Codon 59
|
Codon 61
|
Codon 117
|
Codon 146
|
25 tests
|
|
6
|
6
|
5
|
12
|
4
|
7
|
